Latest stories on HROW
Leerink bullish on Harrow, initiates with an Outperform
The Fly61 · neutralanalyst
Harrow initiated with an Outperform at Leerink
The Fly61 · neutralanalyst
Harrow Health Streamlines Senior Finance and Accounting Leadership
TipRanks50 · neutralgeneral
HARROW, INC. (HROW) files 8-K
SEC 8-K50 · neutralgeneral
Mike Ashley to Fight for Majority Control of Hugo Boss
Yahoo Top48 · neutralm&a
Harrow to Participate in Three Investor Conferences in September
Business Insider56 · neutralgeneral
Harrow to Participate in Three Investor Conferences in September
GlobeNewswire56 · neutralgeneral
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
Yahoo Finance48 · neutralgeneral
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
StockTitan63 · neutralproduct/pr
Harrow (HROW) Q2 2026 Earnings Call Transcript
Yahoo Top73 · bullishearnings
Harrow (HROW) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
Yahoo Top63 · neutralm&a
Harrow: The Q2 Turnaround Is Enough For A Cautious Buy
Seeking Alpha56 · neutralanalyst
Harrow reiterates $350M-$365M 2026 revenue outlook as TYRVAYA is expected to add more than $30M in 2027 revenue
Seeking Alpha56 · neutralproduct/pr
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Harrow Q2 Earnings Call Highlights
Yahoo Finance63 · neutralearnings
Harrow Health, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance50 · neutralearnings
Harrow Health Sees Strong Q2 Growth, Reaffirms 2026 Outlook
TipRanks68 · bullishearnings
Harrow reports Q2 EPS (46c), consensus (24c)
The Fly34 · bearishearnings
Harrow Health GAAP EPS of -$0.46 misses by $0.28, revenue of $70.7M beats by $0.35M
Seeking Alpha34 · bearishearnings
HARROW, INC. (HROW) files 8-K
SEC 8-K50 · neutralgeneral
Harrow Announces Second Quarter 2026 Financial Results
StockTitan50 · neutralearnings
Harrow Health Q2 2026 Earnings Preview
Seeking Alpha34 · bearishearnings
Harrow Health Acquires Global Rights to TYRVAYA Nasal Spray
TipRanks63 · neutralm&a
Viatris posts Q2 beat; sells eye drug Tyrvaya to Harrow for up to $100M
Seeking Alpha63 · neutralm&a